ALNA

Allena Pharmaceuticals, Inc. [ALNA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALNA Stock Summary

In the News

ALNA Financial details

Company Rating
-
Market Cap
0
Income
-27.62M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
15 Aug 2022
P/E
-0.37
Forward P/E
-
PEG
0.05
P/S
-
P/B
2.02
P/C
-
P/FCF
-
Quick Ratio
0.63
Current Ratio
1.58
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.31
EPS next Y
-
EPS next Q
-
EPS this Y
1.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-34.62%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-116%
ROE
-268%
ROC
-2.69%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
-
52W High
-
52W Low
-
RSI
33
Rel Volume
-
Avg Volume
-
Volume
252.31M
Perf Week
3650%
Perf Month
371.7%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.14907
-
-
Volatility
0.03%, 0.01%
Prev Close
4900%
Price
0.075
Change
5257.14%

Something similar

Top by Market Cap
BRK-A
FXAIX
BRK-B
LLY.DE
NVD.DE
Same Sector
KURN.SW
POLB.L
UCBJY
EUZ.DE
SHWZ
Check Those
HNNA
TFIV
TOP-R.BK
200625.SZ
5632.T
Similar Market Cap
BPCL.NS
PODDARHOUS.NS
FST-UN
2615.TW
NYTTO-PREF.ST

Company Profile

Healthcare Biotechnology

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.